Revolutionising the management of viral respiratory tract infections
Breathing new life into at-risk patients by transforming the prevention and treatment of viral respiratory infections
Pneumagen is a clinical-stage biotech company developing Neumifil, its lead product, as an intranasal drug for the prophylaxis and treatment of a broad range of viral respiratory tract infections (RTIs).
Our mission is to develop truly innovative, life-saving, broad-spectrum antiviral therapies for the prevention of infection in at-risk patients, vulnerable to a broad range of respiratory tract infections.
Our lead product
Our lead product, Neumifil is a novel, engineered multivalent Carbohydrate Binding Molecule (mCBM) which is being developed as a broad-spectrum product for the prevention of viral respiratory infections including Influenza Virus (IV), Respiratory Syncytial Virus (RSV), Human Rhinovirus (hRV) and Coronavirus Infections including SARS-CoV-2.
Respiratory viral infections are a major cause of exacerbations in patients with a range of respiratory diseases including, COPD, bronchiectasis and asthma. These exacerbations can accelerate lung function decline and lead to greater morbidity and mortality rates as well as significantly higher healthcare costs.
As a result, there is a significant medical need for the treatment of virally induced pulmonary exacerbations in patients with underlying respiratory diseases.
Currently, there are no treatments approved specifically to prevent infective exacerbations of chronic lung diseases. Without targeted treatment of the disease, therapy can be ineffective and the exacerbations can have a negative impact on the quality of life of patients, accelerate disease progression and result in increased hospital admissions.